The lymph node microenvironment and its role in the progression of metastatic cancer

Seminars in Cell and Developmental Biology

Volumn 38, Issue , 2015, Pages 98-105

  Pereira, Ethel R ^a   Jones, Dennis ^a   Jung, Keehoon ^a   Padera, Timothy P ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Chemokine; Clonality; Lymph node; Lymphangiogenesis; Lymphatic vessels; Metastasis

Indexed keywords

CANCER GROWTH; CANCER SURVIVAL; CLONAL VARIATION; DISEASE COURSE; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; METASTASIS; MICROENVIRONMENT; REVIEW; SENTINEL LYMPH NODE; SOLID TUMOR; ANIMAL; IMMUNE EVASION; IMMUNOLOGICAL MONITORING; IMMUNOLOGY; NEOPLASM; PATHOLOGY; TUMOR MICROENVIRONMENT;

CHEMOKINE;

ANIMALS; CHEMOKINES; HUMANS; IMMUNE EVASION; LYMPH NODES; LYMPHATIC METASTASIS; MONITORING, IMMUNOLOGIC; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84928146002     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2015.01.008     Document Type: Review

References (108)

1. Fidler I.J. Critical determinants of metastasis. Semin Cancer Biol 2002, 12:89-96.
2. Podgrabinska S., Skobe M. Role of lymphatic vasculature in regional and distant metastases. Microvasc Res 2014, 95C:46-52.
3. Kawada K., Taketo M.M. Significance and mechanism of lymph node metastasis in cancer progression. Cancer Res 2011, 71:1214-1218.
4. Edge S.B., Compton C.C. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010, 17:1471-1474.
5. Nathanson S.D., Shah R., Rosso K. Sentinel lymph node metasatses in cancer: causes, detection and their role in disease progression. Semin Cell Dev Biol 2014.
6. Cady B. Regional lymph node metastases, a singular manifestation of the process of clinical metastases in cancer: contemporary animal research and clinical reports suggest unifying concepts. Ann Surg Oncol 2007, 14:1790-1800.
7. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
8. Swartz M.A. Immunomodulatory roles of lymphatic vessels in cancer progression. Cancer Immunol Res 2014, 2:701-707.
9. Padera T.P., Kadambi A., di Tomaso E., Carreira C.M., Brown E.B., Boucher Y., et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002, 296:1883-1886.
10. Padera T.P., Stoll B.R., So P.T., Jain R.K. Conventional and high-speed intravital multiphoton laser scanning microscopy of microvasculature, lymphatics, and leukocyte-endothelial interactions. Mol Imaging 2002, 1:9-15.
11. Hoshida T., Isaka N., Hagendoorn J., di Tomaso E., Chen Y.L., Pytowski B., et al. Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications. Cancer Res 2006, 66:8065-8075.
12. Vakoc B.J., Lanning R.M., Tyrrell J.A., Padera T.P., Bartlett L.A., Stylianopoulos T., et al. Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging. Nat Med 2009, 15:1219-1223.
13. Liao S., Cheng G., Conner D.A., Huang Y., Kucherlapati R.S., Munn L.L., et al. Impaired lymphatic contraction associated with immunosuppression. Proc Natl Acad Sci U S A 2011, 108:18784-18789.
14. Proulx S.T., Luciani P., Christiansen A., Karaman S., Blum K.S., Rinderknecht M., et al. Use of a PEG-conjugated bright near-infrared dye for functional imaging of rerouting of tumor lymphatic drainage after sentinel lymph node metastasis. Biomaterials 2013, 34:5128-5137.
15. Sevick-Muraca E.M., Kwon S., Rasmussen J.C. Emerging lymphatic imaging technologies for mouse and man. J Clin Invest 2014, 124:905-914.
16. Alitalo K. The lymphatic vasculature in disease. Nat Med 2011, 17:1371-1380.
17. Stacker S.A., Williams S.P., Karnezis T., Shayan R., Fox S.B., Achen M.G. Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nat Rev Cancer 2014, 14:159-172.
18. Schmid-Schonbein G.W. Microlymphatics and lymph flow. Physiol Rev 1990, 70:987-1028.
19. Ruddle N.H. Lymphatic vessels and tertiary lymphoid organs. J Clin Invest 2014, 124:953-959.
20. Peinado H., Lavotshkin S., Lyden D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol 2011, 21:139-146.
21. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889, 133:571-573.
22. Harrell M.I., Iritani B.M., Ruddell A. Tumor-induced sentinel lymph node lymphangiogenesis and increased lymph flow precede melanoma metastasis. Am J Pathol 2007, 170:774-786.
23. Chung M.K., Do I.G., Jung E., Son Y.I., Jeong H.S., Baek C.H. Lymphatic vessels and high endothelial venules are increased in the sentinel lymph nodes of patients with oral squamous cell carcinoma before the arrival of tumor cells. Ann Surg Oncol 2012, 19:1595-1601.
24. Qian C.N., Berghuis B., Tsarfaty G., Bruch M., Kort E.J., Ditlev J., et al. Preparing the soil: the primary tumor induces vasculature reorganization in the sentinel lymph node before the arrival of metastatic cancer cells. Cancer Res 2006, 66:10365-10376.
25. Ogawa F., Amano H., Eshima K., Ito Y., Matsui Y., Hosono K., et al. Prostanoid induces premetastatic niche in regional lymph nodes. J Clin Invest 2014, 124:4882-4894.
26. Qian C.N., Resau J.H., Teh B.T. Prospects for vasculature reorganization in sentinel lymph nodes. Cell Cycle 2007, 6:514-517.
27. Kohrt H.E., Nouri N., Nowels K., Johnson D., Holmes S., Lee P.P. Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med 2005, 2:e284.
28. Van den Eynden G.G., Van der Auwera I., Van Laere S.J., Colpaert C.G., Turley H., Harris A.L., et al. Angiogenesis and hypoxia in lymph node metastases is predicted by the angiogenesis and hypoxia in the primary tumour in patients with breast cancer. Br J Cancer 2005, 93:1128-1136.
29. Lee J.H., Torisu-Itakara H., Cochran A.J., Kadison A., Huynh Y., Morton D.L., et al. Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin Cancer Res 2005, 11:107-112.
30. Leong S.P., Peng M., Zhou Y.M., Vaquerano J.E., Chang J.W. Cytokine profiles of sentinel lymph nodes draining the primary melanoma. Ann Surg Oncol 2002, 9:82-87.
31. Poindexter N.J., Sahin A., Hunt K.K., Grimm E.A. Analysis of dendritic cells in tumor-free and tumor-containing sentinel lymph nodes from patients with breast cancer. Breast Cancer Res 2004, 6:R408-R415.
32. Alb M., Sie C., Adam C., Chen S., Becker J.C., Schrama D. Cellular and cytokine-dependent immunosuppressive mechanisms of grm1-transgenic murine melanoma. Cancer Immunol Immunother 2012, 61:2239-2249.
33. Dolcetti L., Peranzoni E., Ugel S., Marigo I., Fernandez Gomez A., Mesa C., et al. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol 2010, 40:22-35.
34. Zhang W., Zhang C., Li W., Deng J., Herrmann A., Priceman S.J., et al. CD8 T-cell immunosurveillance constrains lymphoid pre-metastatic myeloid cell accumulation. Eur J Immunol 2014, 91:411-429.
35. Hirakawa S., Kodama S., Kunstfeld R., Kajiya K., Brown L.F., Detmar M. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med 2005, 201:1089-1099.
36. Hirakawa S., Brown L.F., Kodama S., Paavonen K., Alitalo K., Detmar M. VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood 2007, 109:1010-1017.
37. Garmy-Susini B., Avraamides C.J., Desgrosellier J.S., Schmid M.C., Foubert P., Ellies L.G., et al. PI3Kalpha activates integrin alpha4beta1 to establish a metastatic niche in lymph nodes. Proc Natl Acad Sci U S A 2013, 110:9042-9047.
38. Lee A.S., Kim D.H., Lee J.E., Jung Y.J., Kang K.P., Lee S., et al. Erythropoietin induces lymph node lymphangiogenesis and lymph node tumor metastasis. Cancer Res 2011, 71:4506-4517.
39. Farnsworth R.H., Karnezis T., Shayan R., Matsumoto M., Nowell C.J., Achen M.G., et al. A role for bone morphogenetic protein-4 in lymph node vascular remodeling and primary tumor growth. Cancer Res 2011, 71:6547-6557.
40. Carriere V., Colisson R., Jiguet-Jiglaire C., Bellard E., Bouche G., Al Saati T., et al. Cancer cells regulate lymphocyte recruitment and leukocyte-endothelium interactions in the tumor-draining lymph node. Cancer Res 2005, 65:11639-11648.
41. Deng J., Liu Y., Lee H., Herrmann A., Zhang W., Zhang C., et al. S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. Cancer Cell 2012, 21:642-654.
42. Shields J.D., Borsetti M., Rigby H., Harper S.J., Mortimer P.S., Levick J.R., et al. Lymphatic density and metastatic spread in human malignant melanoma. Br J Cancer 2004, 90:693-700.
43. Karpanen T., Egeblad M., Karkkainen M.J., Kubo H., Yla-Herttuala S., Jaattela M., et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 2001, 61:1786-1790.
44. Skobe M., Hawighorst T., Jackson D.G., Prevo R., Janes L., Velasco P., et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001, 7:192-198.
45. Mandriota S.J., Jussila L., Jeltsch M., Compagni A., Baetens D., Prevo R., et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 2001, 20:672-682.
46. Stacker S.A., Caesar C., Baldwin M.E., Thornton G.E., Williams R.A., Prevo R., et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001, 7:186-191.
47. Issa A., Le T.X., Shoushtari A.N., Shields J.D., Swartz M.A. Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype. Cancer Res 2009, 69:349-357.
48. Zheng W., Aspelund A., Alitalo K. Lymphangiogenic factors, mechanisms, and applications. J Clin Invest 2014, 124:878-887.
49. Karnezis T., Shayan R., Caesar C., Roufail S., Harris N.C., Ardipradja K., et al. VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. Cancer Cell 2012, 21:181-195.
50. Padera T.P., Kuo A.H., Hoshida T., Liao S., Lobo J., Kozak K.R., et al. Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib. Mol Cancer Ther 2008, 7:2272-2279.
51. Gogineni A., Caunt M., Crow A., Lee C.V., Fuh G., van Bruggen N., et al. Inhibition of VEGF-C modulates distal lymphatic remodeling and secondary metastasis. PLoS ONE 2013, 8:e68755.
52. Tammela T., Saaristo A., Holopainen T., Yla-Herttuala S., Andersson L.C., Virolainen S., et al. Photodynamic ablation of lymphatic vessels and intralymphatic cancer cells prevents metastasis. Sci Transl Med 2011, 3:69ra11.
53. Escobar-Prieto A., Gonzalez G., Templeton A.W., Cooper B.R., Palacios E. Lymphatic channel obstruction patterns of altered flow dynamics. Am J Roentgenol Radium Ther Nucl Med 1971, 113:366-375.
54. Nathanson S.D., Shah R., Chitale D.A., Mahan M. Intraoperative clinical assessment and pressure measurements of sentinel lymph nodes in breast cancer. Ann Surg Oncol 2014, 21:81-85.
55. Kwon S., Agollah G.D., Wu G., Sevick-Muraca E.M. Spatio-temporal changes of lymphatic contractility and drainage patterns following lymphadenectomy in mice. PLoS ONE 2014, 9:e106034.
56. Barankay T., Baumgartl H., Lubbers D.W., Seidl E. Oxygen pressure in small lymphatics. Pflugers Arch 1976, 366:53-59.
57. Samet A., Gilbey P., Talmon Y., Cohen H. Vascular transformation of lymph node sinuses. J Laryngol Otol 2001, 115:760-762.
58. Chovatiya R., Medzhitov R. Stress, inflammation, and defense of homeostasis. Mol Cell 2014, 54:281-288.
59. Shweiki D., Itin A., Soffer D., Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359:843-845.
60. Fukumura D., Xavier R., Sugiura T., Chen Y., Park E.C., Lu N., et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 1998, 94:715-725.
61. Roberts N., Kloos B., Cassella M., Podgrabinska S., Persaud K., Wu Y., et al. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res 2006, 66:2650-2657.
62. Arapandoni-Dadioti P., Giatromanolaki A., Trihia H., Harris A.L., Koukourakis M.I. Angiogenesis in ductal breast carcinoma comparison of microvessel density between primary tumour and lymph node metastasis. Cancer Lett 1999, 137:145-150.
63. Naresh K.N., Nerurkar A.Y., Borges A.M. Angiogenesis is redundant for tumour growth in lymph node metastases. Histopathology 2001, 38:466-470.
64. Sonveaux P., Vegran F., Schroeder T., Wergin M.C., Verrax J., Rabbani Z.N., et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 2008, 118:3930-3942.
65. Guillaumond F., Leca J., Olivares O., Lavaut M.N., Vidal N., Berthezene P., et al. Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma. Proc Natl Acad Sci U S A 2013, 110:3919-3924.
66. Koshikawa N., Iyozumi A., Gassmann M., Takenaga K. Constitutive upregulation of hypoxia-inducible factor-1alpha mRNA occurring in highly metastatic lung carcinoma cells leads to vascular endothelial growth factor overexpression upon hypoxic exposure. Oncogene 2003, 22:6717-6724.
67. Das S., Sarrou E., Podgrabinska S., Cassella M., Mungamuri S.K., Feirt N., et al. Tumor cell entry into the lymph node is controlled by CCL1 chemokine expressed by lymph node lymphatic sinuses. J Exp Med 2013, 210:1509-1528.
68. Wiley H.E., Gonzalez E.B., Maki W., Wu M.T., Hwang S.T. Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J Natl Cancer Inst 2001, 93:1638-1643.
69. Ding Y., Shimada Y., Maeda M., Kawabe A., Kaganoi J., Komoto I., et al. Association of CC chemokine receptor 7 with lymph node metastasis of esophageal squamous cell carcinoma. Clin Cancer Res 2003, 9:3406-3412.
70. Cochran A.J., Huang R.R., Lee J., Itakura E., Leong S.P., Essner R. Tumour-induced immune modulation of sentinel lymph nodes. Nat Rev Immunol 2006, 6:659-670.
71. von Andrian U.H., Mempel T.R. Homing and cellular traffic in lymph nodes. Nat Rev Immunol 2003, 3:867-878.
72. Ito M., Minamiya Y., Kawai H., Saito S., Saito H., Nakagawa T., et al. Tumor-derived TGFbeta-1 induces dendritic cell apoptosis in the sentinel lymph node. J Immunol 2006, 176:5637-5643.
73. Huang R.R., Wen D.R., Guo J., Giuliano A.E., Nguyen M., Offodile R., et al. Selective modulation of paracortical dendritic cells and T-lymphocytes in breast cancer sentinel lymph nodes. Breast J 2000, 6:225-232.
74. Watanabe S., Deguchi K., Zheng R., Tamai H., Wang L.X., Cohen P.A., et al. Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes. J Immunol 2008, 181:3291-3300.
75. Podgrabinska S., Kamalu O., Mayer L., Shimaoka M., Snoeck H., Randolph G.J., et al. Inflamed lymphatic endothelium suppresses dendritic cell maturation and function via Mac-1/ICAM-1-dependent mechanism. J Immunol 2009, 183:1767-1779.
76. Tewalt E.F., Cohen J.N., Rouhani S.J., Guidi C.J., Qiao H., Fahl S.P., et al. Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8T cells. Blood 2012, 120:4772-4782.
77. Lund A.W., Duraes F.V., Hirosue S., Raghavan V.R., Nembrini C., Thomas S.N., et al. VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics. Cell Rep 2012, 1:191-199.
78. Preynat-Seauve O., Contassot E., Schuler P., Piguet V., French L.E., Huard B. Extralymphatic tumors prepare draining lymph nodes to invasion via a T-cell cross-tolerance process. Cancer Res 2007, 67:5009-5016.
79. Topalian S.L., Drake C.G., Pardoll D.M. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012, 24:207-212.
80. Deng L., Zhang H., Luan Y., Zhang J., Xing Q., Dong S., et al. Accumulation of foxp3+ T regulatory cells in draining lymph nodes correlates with disease progression and immune suppression in colorectal cancer patients. Clin Cancer Res 2010, 16:4105-4112.
81. Zippelius A., Batard P., Rubio-Godoy V., Bioley G., Lienard D., Lejeune F., et al. Effector function of human tumor-specific CD8T cells in melanoma lesions: a state of local functional tolerance. Cancer Res 2004, 64:2865-2873.
82. Hargadon K.M., Brinkman C.C., Sheasley-O'neill S.L., Nichols L.A., Bullock T.N., Engelhard V.H. Incomplete differentiation of antigen-specific CD8T cells in tumor-draining lymph nodes. J Immunol 2006, 177:6081-6090.
83. Ruddell A., Harrell M.I., Furuya M., Kirschbaum S.B., Iritani B.M. B lymphocytes promote lymphogenous metastasis of lymphoma and melanoma. Neoplasia 2011, 13:748-757.
84. Li Q., Grover A.C., Donald E.J., Carr A., Yu J., Whitfield J., et al. Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells. J Immunol 2005, 175:1424-1432.
85. Li Q., Teitz-Tennenbaum S., Donald E.J., Li M., Chang A.E. In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy. J Immunol 2009, 183:3195-3203.
86. Zirakzadeh A.A., Marits P., Sherif A., Winqvist O. Multiplex B cell characterization in blood, lymph nodes, and tumors from patients with malignancies. J Immunol 2013, 190:5847-5855.
87. Li Q., Lao X., Pan Q., Ning N., Yet J., Xu Y., et al. Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression. Clin Cancer Res 2011, 17:4987-4995.
88. McFadden D.G., Papagiannakopoulos T., Taylor-Weiner A., Stewart C., Carter S.L., Cibulskis K., et al. Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. Cell 2014, 156:1298-1311.
89. Naxerova K., Brachtel E., Salk J.J., Seese A.M., Power K., Abbasi B., et al. Hypermutable DNA chronicles the evolution of human colon cancer. Proc Natl Acad Sci U S A 2014, 111:E1889-E1898.
90. Hack T.F., Cohen L., Katz J., Robson L.S., Goss P. Physical and psychological morbidity after axillary lymph node dissection for breast cancer. J Clin Oncol 1999, 17:143-149.
91. Giuliano A.E., Hunt K.K., Ballman K.V., Beitsch P.D., Whitworth P.W., Blumencranz P.W., et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011, 305:569-575.
92. Galimberti V., Cole B.F., Zurrida S., Viale G., Luini A., Veronesi P., et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 2013, 14:297-305.
93. Straver M.E., Meijnen P., van Tienhoven G., van de Velde C.J., Mansel R.E., Bogaerts J., et al. Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer. J Clin Oncol 2010, 28:731-737.
94. Rutgers E.J., Donker M., Straver M.E., Meijnen P., Van De Velde C.J.H., Mansel R.E., et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients: final analysis of the EORTC AMAROS trial (10981/22023). J Clin Oncol 2013, (suppl. abstr LBA1001).
95. Veronesi U., Viale G., Paganelli G., Zurrida S., Luini A., Galimberti V., et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg 2010, 251:595-600.
96. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002, 29:15-18.
97. Matsumoto M., Roufail S., Inder R., Caesar C., Karnezis T., Shayan R., et al. Signaling for lymphangiogenesis via VEGFR-3 is required for the early events of metastasis. Clin Exp Metastasis 2013, 30:819-832.
98. Kuerer H.M., Newman L.A., Smith T.L., Ames F.C., Hunt K.K., Dhingra K., et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999, 17:460-469.
99. Cox C., Holloway C.M., Shaheta A., Nofech-Mozes S., Wright F.C. What is the burden of axillary disease after neoadjuvant therapy in women with locally advanced breast cancer. Curr Oncol 2013, 20:111-117.
100. Ebctcg McGale P., Taylor C., Correa C., Cutter D., Duane F., et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 2014, 383:2127-2135.
101. Huston T.L., Pressman P.I., Moore A., Vahdat L., Hoda S.A., Kato M., et al. The presentation of contralateral axillary lymph node metastases from breast carcinoma: a clinical management dilemma. Breast J 2007, 13:158-164.
102. Courdi A., Chamorey E., Ferrero J.M., Hannoun-Levi J.M. Influence of internal mammary node irradiation on long-term outcome and contralateral breast cancer incidence in node-negative breast cancer patients. Radiother Oncol 2013, 108:259-265.
103. Pasquali S., Mocellin S., Mozzillo N., Maurichi A., Quaglino P., Borgognoni L., et al. Nonsentinel lymph node status in patients with cutaneous melanoma: results from a multi-institution prognostic study. J Clin Oncol 2014, 32:935-941.
104. Wu F., Tamhane M., Morris M.E. Pharmacokinetics, lymph node uptake, and mechanistic PK model of near-infrared dye-labeled bevacizumab after IV and SC administration in mice. AAPS J 2012, 14:252-261.
105. Fletcher C.V., Staskus K., Wietgrefe S.W., Rothenberger M., Reilly C., Chipman J.G., et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A 2014, 111:2307-2312.
106. Freeling J.P., Ho R.J. Anti-HIV drug particles may overcome lymphatic drug insufficiency and associated HIV persistence. Proc Natl Acad Sci U S A 2014, 111:E2512-E2513.
107. Thomas S.N., Vokali E., Lund A.W., Hubbell J.A., Swartz M.A. Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response. Biomaterials 2014, 35:814-824.
108. Fujita T., Teramoto K., Ozaki Y., Hanaoka J., Tezuka N., Itoh Y., et al. Inhibition of transforming growth factor-beta-mediated immunosuppression in tumor-draining lymph nodes augments antitumor responses by various immunologic cell types. Cancer Res 2009, 69:5142-5150.